Breaking News
Get 40% Off 0
📈 Free Gift Friday: Instantly Copy Legendary Investors' Portfolios Copy for Free
Close

Virtus Kar Health Sciences Fund Class A (RAGHX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
30.05 +0.31    +1.04%
08:00:00 - Delayed Data. Currency in USD ( Disclaimer )
Type:  Fund
Market:  United States
Issuer:  Allianz Funds
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 130.31M
AllianzGI Health Sciences A 30.05 +0.31 +1.04%

Virtus Kar Health Sciences Fund Class A Overview

 
On this page you'll find an in-depth profile of Virtus Kar Health Sciences Fund Class A. Learn about the key management, total assets, investment strategy and contact information of RAGHX among other information.
Category

Health

Total Assets

130.31M

Expenses

1.39%

Inception Date

37292

Investment Strategy

The investment seeks long-term capital appreciation. The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio manager considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities.

Contact Information

Address Greenfield, MA, 01301
Greenfield,MA 01301
United States
Phone +1 8002431574

Top Executives

Name Title Since Until
Jon K Christensen Portfolio Manager 2022 Now
Biography Jon Christensen, CFA, Portfolio Manager | Mr. Christensen is a Portfolio Manager and a Senior Research Analyst with primary research responsibilities for the small and mid-capitalization health-care sector. Before joining Kayne Anderson Rudnick in 2001, Mr. Christensen was a Portfolio Manager and Senior Research Analyst for Doheny Asset Management and has approximately 18 years of equity research experience. He earned a B.S. in Mathematics/Applied Science from the University of California, Los Angeles, and an M.B.A. from the California State University, Long Beach. Mr. Christensen is a Chartered Financial Analyst charterholder.
Chris Armbruster Portfolio Manager + Senior Research Analyst 2022 Now
Biography Mr. Armbruster is a Portfolio Manager and Research Analyst at KAR with primary research responsibilities for the large-capitalization consumer discretionary, health care, and information technology sectors. Before joining Kayne Anderson Rudnick in 2013, Mr. Armbruster worked at B. Riley & Co. as an associate analyst covering special situations, and at Al Frank Asset Management as a vice president in equity research.
Christopher Chin - 2020 2022
Peter Pirsch Senior Portfolio Manager 2018 2022
Biography Mr. Pirsch is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 20 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an associate director at UBS Investment Bank and an analyst at Wells Fargo. He has a B.A. in economics and international relations from Bucknell University, and an M.B.A. with a certificate in health sector management from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder.
Bret Jones Portfolio Manager 2018 2019
Biography Mr. Jones is a portfolio manager, senior analyst and a director with Allianz Global Investors, which he joined in 2018. He is a member of the Health Care team covering health care services companies.He was previously a senior health care analyst at Pura Vida Investments; Oppenheimer; Brean Murray, Carret and Leerink Swann. Before that, Mr. Jones was an equity research associate at SG Cowen. He has a B.S., magna cum laude, in finance from Florida State University, and an M.B.A. from Kelley School of Business, Indiana University. Mr. Jones is a CFA charterholder.
John R. Schroer Portfolio Manager 2014 2018
Biography Mr. Schroer, CFA, is a portfolio manager and a director with Allianz Global Investors, which he joined in 2014. He is the sector head of the Health Care team. He was previously the president of Schroer Capital, L.P.; an equity analyst with HealthCor Management, L.P.; a managing member and portfolio manager for ITROS Capital Management, LLC; a global partner, senior vice president, and portfolio manager for INVESCO; and an analyst for Trust Company of the West. Mr. Schroer has a B.S. in history and international relations and an M.B.A. in finance from the University of Wisconsin.
Michael Dauchot Portfolio Manager 2005 2018
Biography Dr. Dauchot, CFA, is a portfolio manager, a senior research analyst and a director with Allianz Global Investors, which he joined in 1999. He is a member of the Health Care team, focusing on medical technology, life-science tools and diagnostics. He previously worked at Pequot Capital Management and BancBoston Robertson Stephens. Dr. Dauchot has a degree in chemistry from Case Western Reserve University, an M.B.A. from the Kellogg School of Management at Northwestern University and an M.D. from the University of Cincinnati College of Medicine.
Paul A. Wagner Senior Research Analyst 2008 2014
Biography Mr. Wagner, CFA, is a portfolio manager, a senior research analyst and a director with Allianz Global Investors, which he joined in 2006. He has biotechnology responsibilities for the US Health Care team and has 14 years of investment-industry experience. Mr. Wagner previously worked at PDL BioPharma in corporate and business development, and was a vice president and senior equity-research analyst in the biotechnology sector at Lehman Brothers. He has a B.S. in chemistry from the University of Wisconsin and a Ph.D. in chemistry from the California Institute of Technology.
Ken H. Tsuboi Health Care team 2007 2013
Biography Ken joined RCM in 1996, beginning his work on the Health Care team in 2000. Ken covers international healthcare companies, analyzing stocks for recommendation to the international portfolio management team. Previously, Mr. Tsuboi was an Asset Backed Analyst for RCM's fixed income team, where he was responsible for the implementation, strategy and evaluation of all asset- backed products. Prior to RCM, Ken was a Senior Portfolio Strategist at Payden & Rygel.
Dan Hunt Member 2008 2013
Biography Dan was responsible for proprietary and client-directed investment idea generation across sectors, with an emphasis on healthcare. He was appointed (as the youngest member) to SG Cowen’s seven-person Investment Policy Committee. Prior to joining SG Cowen, Dan worked for Thomson Financial/Carson in New York as a Senior Associate within Capital Markets Intelligence. Dan holds the Chartered Financial Analyst designation.
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RAGHX Comments

Write your thoughts about Virtus Kar Health Sciences Fund Class A
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email